Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Darrell R Fisher

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
American Journal of Hematology|April 4, 2020
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphomaVictor A Chow, Joseph G Rajendran, Darrell R Fisher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2020
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic MalignanciesManuela Matesan, Darrell R Fisher, Roger Wong, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 27, 2014
Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndromeRaya Mawad, Ted A Gooley, Joseph G Rajendran, et al.
Medical Physics|July 3, 2015
Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID cameraBrian W Miller, Sofia H L Frost, Shani L Frayo, et al.
Blood|May 27, 2011
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft modelJohn M Pagel, Aimee L Kenoyer, Tom Bäck, et al.
Blood|October 29, 2005
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remissionJohn M Pagel, Frederick R Appelbaum, Janet F Eary, et al.
Blood|November 22, 2017
CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignanciesDamian J Green, Shyril O'Steen, Yukang Lin, et al.
Cancer Research|December 28, 2013
A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignanciesDamian J Green, Nural N Orgun, Jon C Jones, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 17, 2015
MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical TherapyMichael Ljungberg, Anna Celler, Mark W Konijnenberg, et al.
Cancer Research|September 4, 2016
Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell CancersDamian J Green, Shani L Frayo, Yukang Lin, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
American Journal of Hematology|April 4, 2020
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphomaVictor A Chow, Joseph G Rajendran, Darrell R Fisher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2020
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic MalignanciesManuela Matesan, Darrell R Fisher, Roger Wong, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 27, 2014
Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndromeRaya Mawad, Ted A Gooley, Joseph G Rajendran, et al.
Medical Physics|July 3, 2015
Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID cameraBrian W Miller, Sofia H L Frost, Shani L Frayo, et al.
Blood|May 27, 2011
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft modelJohn M Pagel, Aimee L Kenoyer, Tom Bäck, et al.
Blood|October 29, 2005
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remissionJohn M Pagel, Frederick R Appelbaum, Janet F Eary, et al.
Blood|November 22, 2017
CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignanciesDamian J Green, Shyril O'Steen, Yukang Lin, et al.
Cancer Research|December 28, 2013
A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignanciesDamian J Green, Nural N Orgun, Jon C Jones, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 17, 2015
MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical TherapyMichael Ljungberg, Anna Celler, Mark W Konijnenberg, et al.
Cancer Research|September 4, 2016
Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell CancersDamian J Green, Shani L Frayo, Yukang Lin, et al.
Pageof 9